Form 4: Aehr Test Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Aehr Test Systems Director Laura Oliphant sold 4,546 shares of common stock on January 22, 2026, under a pre-arranged 10b5-1 trading plan.
Summary
- Laura Oliphant, a Director of Aehr Test Systems, sold a total of 4,546 shares of common stock.
- The sales occurred on January 22, 2026, at weighted average prices ranging from $31.38 to $31.485 per share.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan, which allows insiders to sell shares at a predetermined time or price.
- Following these sales, Laura Oliphant directly owns 18,432 shares and indirectly owns 7,665 shares through a trust.
- The directly owned amount includes shares subject to unvested restricted stock units.
Sentiment
Score: 5
Explanation: The sale of shares by a director could be viewed slightly negatively, but the disclosure that it was part of a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, making the sentiment neutral.
Negatives
- A Director sold 4,546 shares of common stock, which reduces their direct ownership in the company.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Laura Oliphant granted a Power of Attorney to specific individuals (Gayn Erickson, Chris Siu, Adil Engineer, Vernon Rogers) to execute and file Section 16 forms (Forms 3, 4, and 5) on her behalf. | June 2, 2023 | Streamlines compliance with Section 16 reporting requirements for the director, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders may note a slight reduction in direct insider ownership, though the impact is minimal given the pre-planned nature of the sale and the remaining holdings.
Key Dates
| Date | Description |
|---|---|
| June 2, 2023 | Date Power of Attorney was executed by Laura Oliphant for Section 16 filings. |
| January 22, 2026 | Date of common stock transactions by Laura Oliphant. |
| January 26, 2026 | Date Form 4 was signed by attorney-in-fact Chris Siu. |
Recommendation
holdThis Form 4 filing reports routine insider sales executed under a pre-arranged 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental prospects or management's confidence, and therefore, do not warrant a change in investment recommendation based solely on this filing.
Keywords
Aehr Test Systems, AEHR, Insider Trading, Form 4, Stock Sale, Director, Laura Oliphant, 10b5-1 Plan, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.